CN118955717A - Dll3靶向抗体及其用途 - Google Patents

Dll3靶向抗体及其用途 Download PDF

Info

Publication number
CN118955717A
CN118955717A CN202411174926.2A CN202411174926A CN118955717A CN 118955717 A CN118955717 A CN 118955717A CN 202411174926 A CN202411174926 A CN 202411174926A CN 118955717 A CN118955717 A CN 118955717A
Authority
CN
China
Prior art keywords
antibody
dll
seq
antibodies
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202411174926.2A
Other languages
English (en)
Chinese (zh)
Inventor
J·T·普瓦里耶
C·鲁丁
J·路易斯
A·汗
D·安德鲁
X·陈
I·洛伦兹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Third Hospital Treatment Research Institute
Memorial Sloan Kettering Cancer Center
Original Assignee
Third Hospital Treatment Research Institute
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Third Hospital Treatment Research Institute, Memorial Sloan Kettering Cancer Center filed Critical Third Hospital Treatment Research Institute
Publication of CN118955717A publication Critical patent/CN118955717A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202411174926.2A 2019-07-11 2020-07-08 Dll3靶向抗体及其用途 Pending CN118955717A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962872915P 2019-07-11 2019-07-11
US62/872,915 2019-07-11
CN202080062231.9A CN114341182B (zh) 2019-07-11 2020-07-08 Dll3靶向抗体及其用途
PCT/US2020/041282 WO2021007371A1 (en) 2019-07-11 2020-07-08 Dll3-targeting antibodies and uses thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202080062231.9A Division CN114341182B (zh) 2019-07-11 2020-07-08 Dll3靶向抗体及其用途

Publications (1)

Publication Number Publication Date
CN118955717A true CN118955717A (zh) 2024-11-15

Family

ID=74115317

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202411174926.2A Pending CN118955717A (zh) 2019-07-11 2020-07-08 Dll3靶向抗体及其用途
CN202411174923.9A Pending CN119080930A (zh) 2019-07-11 2020-07-08 Dll3靶向抗体及其用途
CN202080062231.9A Active CN114341182B (zh) 2019-07-11 2020-07-08 Dll3靶向抗体及其用途

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202411174923.9A Pending CN119080930A (zh) 2019-07-11 2020-07-08 Dll3靶向抗体及其用途
CN202080062231.9A Active CN114341182B (zh) 2019-07-11 2020-07-08 Dll3靶向抗体及其用途

Country Status (13)

Country Link
US (1) US12441789B2 (https=)
EP (1) EP3997127A4 (https=)
JP (2) JP7661299B2 (https=)
KR (1) KR20220034167A (https=)
CN (3) CN118955717A (https=)
AU (1) AU2020310894A1 (https=)
BR (1) BR112022000216A2 (https=)
CA (1) CA3146566A1 (https=)
CO (1) CO2022001195A2 (https=)
IL (1) IL289585A (https=)
MX (1) MX2022000325A (https=)
PH (1) PH12022550056A1 (https=)
WO (1) WO2021007371A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2718257T3 (https=) * 2014-05-30 2018-04-14
CN118955717A (zh) * 2019-07-11 2024-11-15 纪念斯隆凯特琳癌症中心 Dll3靶向抗体及其用途
CA3204628A1 (en) * 2021-01-13 2022-07-21 John T. POIRIER Antibody-pyrrolobenzodiazepine derivative conjugate
TW202245844A (zh) * 2021-01-13 2022-12-01 紀念斯隆凱特琳癌症中心 抗dll3抗體-藥物結合物
CN117529337A (zh) * 2021-05-08 2024-02-06 上海齐鲁制药研究中心有限公司 针对dll3的结合分子及其应用
JP2024532486A (ja) * 2021-09-02 2024-09-05 メモリアル スローン ケタリング キャンサー センター Ｄｌｌ３を標的とする抗原認識受容体及びその使用
WO2023034566A1 (en) * 2021-09-02 2023-03-09 Memorial Sloan-Kettering Cancer Center Anti-dll3 antibodies and uses thereof
WO2023034557A1 (en) * 2021-09-02 2023-03-09 Memorial Sloan-Kettering Cancer Center Radioligand binding to anti-dll3 antibodies for pretargeted pet imaging and therapeutic uses thereof
TW202346346A (zh) * 2021-12-23 2023-12-01 大陸商江蘇恆瑞醫藥股份有限公司 抗ｄｌｌ３抗體、其抗體－藥物偶聯物及其醫藥用途
KR20240149438A (ko) 2022-02-27 2024-10-14 베링거 인겔하임 인터내셔날 게엠베하 Cd277 및 종양-항원에 대한 이중특이적 항체
CN116003628A (zh) * 2022-08-15 2023-04-25 南京博安生物技术有限公司 靶向人dll3抗原的全人源特异性嵌合抗原受体及其应用
WO2025184421A1 (en) * 2024-02-28 2025-09-04 Juno Therapeutics, Inc. Chimeric antigen receptors and antibodies specific for delta-like ligand 3 (dll3) and related methods

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005016111A2 (en) 2003-08-08 2005-02-24 Abgenix, Inc. Antibodies directed to parathyroid hormone (pth) and uses thereof
US7718774B2 (en) * 2006-11-08 2010-05-18 Macrogenics, Inc. TES7 and antibodies that bind thereto
EP3907242A1 (en) * 2010-01-29 2021-11-10 Chugai Seiyaku Kabushiki Kaisha Anti-dll3 antibody
WO2012013813A1 (en) 2010-07-30 2012-02-02 Gianluca Moroncini Epitopes of the human pdgf receptor able to bind human auto-antibodies, antibodies and uses thereof
EP3453723B1 (en) * 2012-01-31 2021-08-11 Regeneron Pharmaceuticals, Inc. Anti-asic1 antibodies and uses thereof
PE20190658A1 (es) * 2012-02-24 2019-05-08 Abbvie Stemcentrx Llc Moduladores y metodos de empleo novedosos
PE20161209A1 (es) 2014-02-21 2016-11-10 Abbvie Stemcentrx Llc Conjugados de anticuerpos anti-drosophila similar a delta 3 (anti-dll3) y medicamentos para usarse en el tratamiento contra melanoma
AR101669A1 (es) 2014-07-31 2017-01-04 Amgen Res Munich Gmbh Constructos de anticuerpos para cdh19 y cd3
RS61010B1 (sr) * 2014-11-20 2020-11-30 Hoffmann La Roche Bispecifični antigen vezujući molekuli koji aktiviraju t ćelije protiv folr1 i cd3
CN118955717A (zh) * 2019-07-11 2024-11-15 纪念斯隆凯特琳癌症中心 Dll3靶向抗体及其用途

Also Published As

Publication number Publication date
US20220348648A1 (en) 2022-11-03
EP3997127A4 (en) 2023-08-23
EP3997127A1 (en) 2022-05-18
CA3146566A1 (en) 2021-01-14
BR112022000216A2 (pt) 2022-05-17
JP2025156278A (ja) 2025-10-14
PH12022550056A1 (en) 2023-04-12
MX2022000325A (es) 2022-03-25
WO2021007371A1 (en) 2021-01-14
CN114341182B (zh) 2024-09-10
CN119080930A (zh) 2024-12-06
US12441789B2 (en) 2025-10-14
KR20220034167A (ko) 2022-03-17
CO2022001195A2 (es) 2022-03-08
IL289585A (en) 2022-03-01
JP2022540611A (ja) 2022-09-16
AU2020310894A1 (en) 2022-02-03
JP7661299B2 (ja) 2025-04-14
CN114341182A (zh) 2022-04-12

Similar Documents

Publication Publication Date Title
CN114341182B (zh) Dll3靶向抗体及其用途
US12441793B2 (en) CD33 antibodies and methods of using the same to treat cancer
CN114929743B (zh) 抗steap1抗体及其用途
JP2023138957A (ja) Ａ３３抗体組成物および放射性免疫療法におけるその使用方法
CN114401744B (zh) 用于治疗癌症的抗cd33抗体
US20250340637A1 (en) Cd3 targeting antibodies and uses thereof
CN114341176A (zh) Cd19抗体及其使用方法
US20220177581A1 (en) Cd22 antibodies and methods of using the same
CN112566642A (zh) 抗聚唾液酸抗体及其用途
US20220242967A1 (en) Anti-glypican-3 antibodies and uses thereof
US20260042860A1 (en) Anti-cd24 antibodies and uses thereof
RU2839959C2 (ru) Dll3-нацеливающие антитела и их применения
WO2024226646A2 (en) Dlk1 -targeting antibodies and uses thereof
EA046795B1 (ru) Композиции на основе антител против a33 и способы их применения в радиоиммунотерапии

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination